Issues
-
Cover Image
Cover Image
Pancreatic cancer is the most aggressive tumor, showing almost identical incidence and mortality values. Emerging data have highlighted the paramount contribution of tumor epithelium-stroma cross-talk in tumor progression. Galectin-1, a glycan-binding protein, is highly expressed in the stroma of pancreatic ductal tumors from Ela-myc mice, suggesting a role in cancer progression. Interestingly, genetic depletion of Galectin-1 in this model decreases tumor proliferation, angiogenesis, stroma formation and acinar to ductal metaplasia, and restores the immune surveillance, leading to a significant increase in animal lifespan. These results show that Galectin-1 favors tumor progression by modulation of the tumor microenvironment, suggesting that this lectin is a potential target for therapy. For details, see article by Martínez-Bosch and colleagues on page 3512. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Review
The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?
Perspective
Meeting Report
Clinical Studies
Microenvironment and Immunology
Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15
Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell–Activating Receptor NKp30
Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4+ T-Cell Responses through the PD-1–PD-L1 Axis
Complement C5a Receptor Facilitates Cancer Metastasis by Altering T-Cell Responses in the Metastatic Niche
Autologous T-cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastoma
Molecular and Cellular Pathobiology
Galectin-1 Drives Pancreatic Carcinogenesis through Stroma Remodeling and Hedgehog Signaling Activation
Prevention and Epidemiology
No Causal Association Identified for Human Papillomavirus Infections in Lung Cancer
Therapeutics, Targets, and Chemical Biology
Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency
Tumor and Stem Cell Biology
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.